Aurobindo gets final approval for Omeprazole
Aurobindo Pharma announced that the company has received the final approval from the US Food & Drug Administration ( USFDA) to manufacture and market Omeprazole Delayed-release Capsules USP, 10mg, 20mg and 40mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Prilosec® Delayed-release Capsules, 10mg, 20mg and 40mg of AstraZeneca Pharmaceuticals.
Crude oil declines further; Brent at $47
Crude oil declined further; Brent at $47 and WTI at $ 40, new low - Positive for OMC’s , Paints, Lubricants and Tyre companies .Crude Oil ( Brent) has slipped again and is now trading below 5 year low at $ 46.92, while WTI Oil is hovering around $40. As a result the industries which use crude and its derivatives are expected to be beneficial. Positive for OMCs (HPCL, BPCL), Paint (Asian Paints) and lubricants (Castrol, Gulf oil lubricant)
Lupin gets USFDA nod for Fenofibrate tablets; stk jumps
Shares of Lupin surged over 8%, touching to Rs1939.9, after pharma major said it has received approval from USFDA for Fenofibrate tablets in dosages of 160 mg and 54 mg. Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
Ratnamani Metals bags new order worth Rs159.40 cr
Ratnamani Metals & Tubes has announced that the Company has bagged an order for supply of coated CS pipes from Reliance Gas Pipelines amounting to Rs159.40 crores (net of taxes and duties) to be completed in current financial year.
Sun Pharma gets USFDA approval for Ximino
Sun Pharma gets USFDA approval for Ximino: Positive for the company .Sun Pharma gets US FDA approval for Supplemental New Drug Application (sNDA) for Ximino. This approval further strengthens the Company’s branded dermatology portfolio in the US. It expects Ximino TM extended-release capsules to be available for patients during the fourth quarter of 2015.